Therapy with transcutaneous administration of imiquimod combined with oral administration of sorafenib suppresses renal cell carcinoma growing in an orthotopic mouse model

Imiquimod is an imidazoquinoline immune response modifier that is used in antiviral and antiallergic creams. Combination therapy using transcutaneous imiquimod and oral sorafenib was previously demonstrated to reduce the tumor burden of renal cell carcinoma growing cutaneously in a mouse model. In t...

Full description

Saved in:
Bibliographic Details
Published in:Oncol Lett
Main Authors: Karashima, Takashi, Udaka, Keiko, Niimura, Mayumi, Suzuki, Katsuhide, Osakabe, Hiroto, Shimamoto, Tsutomu, Fukata, Satoshi, Inoue, Keiji, Kuroda, Naoto, Seiki, Motoharu, Shuin, Taro
Format: Artigo
Language:Inglês
Published: D.A. Spandidos 2017
Subjects:
Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5494610/
https://ncbi.nlm.nih.gov/pubmed/28693290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.6235
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items